Codexis (CDXS) CFO Erbez Georgia Sells $8.6K of Stock
Codexis CFO Erbez Georgia sold 6,335 shares for $8,619.40 on October 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Erbez Georgia, Chief Financial Officer and Chief Business Officer at Codexis, Inc. ($CDXS), sold 6,335 shares at an average price of $1.36, worth about $8,619.40, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 12.1% to date (from the $1.41 close on Oct 12, 2026).
CDXS
Codexis, Inc.
Key Points
- Erbez Georgia, CFO of Codexis, Inc., sold 6,335 shares at a price of $1.36 each on October 12, 2026, totaling $8,619.40.
- The stock recently traded around $1.25, which is 14.5% below its 50-day moving average and 32.1% below its 200-day average.
- Codexis has a market cap of about $135.8 million and is set to report earnings on November 5, 2026.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
Codexis, Inc. Chief Financial Officer Erbez Georgia sold 6,335 shares on October 12, 2026, for a total of $8,619.40. The sale price was $1.36 per share. This transaction is not part of a planned selling strategy.
Inside Erbez Georgia's Trade
The share price of $1.36 reflects a challenging market for Codexis, which has seen its stock trading below key moving averages.
Other Institutional Activity in Codexis
In recent filings, Blackrock Inc. increased its holdings by 255,838 shares, bringing its total to 7,284,352 shares worth about $9.03 million. Millennium Management LLC also made a notable move, adding 1,550,912 shares, bringing its total to 5,549,139 shares valued at approximately $6.88 million. Meanwhile, Aberdeen Group plc trimmed its position, reducing its stake by 1,910,587 shares, now holding 6,769,954 shares worth about $8.39 million.
Codexis, Inc. Stock Down 8.5%
As of October 16, 2026, Codexis shares are trading recently around $1.25, which is significantly below both its 50-day average of $1.46 and its 200-day average of $1.84. The stock is also 58.1% below its 52-week high of $2.98 but remains 30.2% above its 52-week low of $0.96.
Recent Earnings
Codexis reported trailing twelve-month revenue of $77.7 million, but its net margin stands at -39.6%, reflecting ongoing challenges in profitability. The company is scheduled to announce its next earnings on November 5, 2026.
Insider Buying and Selling at Codexis, Inc.
Earlier this year, several insiders, including De Vre Raymond and Cynthia Collins, bought 66,350 shares each on June 17, 2026. This activity came as the stock traded near $2.57, indicating some level of confidence among company leaders despite the recent downturn.
Analysts Set New Price Targets
On August 17, 2026, Piper Sandler maintained an Overweight rating on Codexis with a price target of $8.00, down from a previous target of $9.00. The consensus among analysts suggests a mean price target of $6.14 based on seven opinions.
About Codexis, Inc.
Codexis, Inc. focuses on developing technology solutions for the manufacturing of therapeutics, especially through its proprietary CodeEvolver technology. This platform helps in discovering and commercializing new enzymes, boosting its position in the biotechnology sector.
Bottom Line
Erbez Georgia's recent sale adds to the narrative of insider trading at Codexis amid fluctuating stock performance. Investors should watch for the upcoming earnings report on November 5, 2026, for further insights into the company's financial health.
Related Filing Alerts
Source: Erbez Georgia's Form 4 filing on $CDXS (Oct 12, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts